Paroxysmal nocturnal hemoglobinuria - Wikipedia, the free encyclopedia
A new monoclonal antibody, eculizumab, protects blood cells against immune destruction by inhibiting the complement system. It has been shown to reduce the need for blood ...
Efalizumab - Wikipedia, the free encyclopedia
Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a medication designed to ... Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, ...
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria - Full Text ...
This study will evaluate the safety and effectiveness of the experimental drug eculizumab for treating paroxysmal nocturnal hemoglobinuria (PNH), a disorder that can cause ...
Safety and Efficacy Study of Eculizumab in Patients With Refractory ...
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various ...
The complement inhibitor eculizumab in paroxysmal nocturnal ...
1: N Engl J Med. 2006 Sep 21;355(12):1233-43. Comment in: N Engl J Med. 2006 Dec 28;355(26):2786; author reply 2787-8. N Engl J Med. 2006 Dec 28;355(26):2786; author reply 2787-8.
CIGNA - eculizumab
Eculizumab affects your immune system, and using this medication may increase your risk of serious infection such as meningitis. Get emergency medical help if you have any signs of ...
Eculizumab
B lueCross BlueShield of Tennessee Medical Policy Manual. Eculizumab. DESCRIPTION. Eculizumab, a recombinant monoclonal antibody, binds to the complement protein C5 and inhibits ...
Eculizumab
FDA approves Soliris for the treatment of paroxysmal nocturnal hemoglobinuria. On March 16, 2007 the U.S. Food and Drug Administration granted approval to eculizumab injection ...
